BACKGROUND: Alpha-mannosidosis (OMIM 248500) is a rare lysosomal storage disease (LSD) caused by alpha-mannosidase deficiency. Manifestations include intellectual disabilities, facial characteristics and hearing impairment. A recombinant human alpha-mannosidase (rhLAMAN) has been developed for weekly intravenous enzyme replacement therapy (ERT). We present the preliminary data after 12 months of treatment. METHODS: This is a phase I-II study to evaluate safety and efficacy of rhLAMAN. Ten patients (7-17 y) were treated. We investigated efficacy by testing motor function (6-minutes-Walk-Test (6-MWT), 3-min-Stair-Climb-Test (3-MSCT), The Bruininks-Oseretsky Test of Motor Proficiency (BOT2), cognitive function (Leiter-R), oligosaccharides in serum, urine and CSF and Tau- and GFA-protein in CSF. RESULTS: Oligosaccharides: S-, U- and CSF-oligosaccharides decreased 88.6% (CI -92.0 -85.2, p < 0.001), 54.1% (CI -69.5- -38.7, p < 0,001), and 25.7% (CI -44.3- -7.1, p < 0.05), respectively. Biomarkers: CSF-Tau- and GFA-protein decreased 15%, p < 0.009) and 32.5, p < 0.001 respectively. Motor function: Improvements in 3MSCT (31 steps (CI 6.8-40.5, p < 0.01) and in 6MWT (60.4 m (CI -8.9 -51.1, NS) were achieved. Cognitive function: Improvement in the total Equivalence Age of 4 months (0.34) was achieved in the Leiter R test (CI -0.2-0.8, NS). CONCLUSIONS: These data suggest that rhLAMAN may be an encouraging new treatment for patients with alpha-mannosidosis.The study is designed to continue for a total of 18 months. Longer-term follow-up of patients in this study and the future placebo-controlled phase 3 trial are needed to provide greater support for the findings in this study.
RCT Entities:
BACKGROUND: Alpha-mannosidosis (OMIM 248500) is a rare lysosomal storage disease (LSD) caused by alpha-mannosidase deficiency. Manifestations include intellectual disabilities, facial characteristics and hearing impairment. A recombinant human alpha-mannosidase (rhLAMAN) has been developed for weekly intravenous enzyme replacement therapy (ERT). We present the preliminary data after 12 months of treatment. METHODS: This is a phase I-II study to evaluate safety and efficacy of rhLAMAN. Ten patients (7-17 y) were treated. We investigated efficacy by testing motor function (6-minutes-Walk-Test (6-MWT), 3-min-Stair-Climb-Test (3-MSCT), The Bruininks-Oseretsky Test of Motor Proficiency (BOT2), cognitive function (Leiter-R), oligosaccharides in serum, urine and CSF and Tau- and GFA-protein in CSF. RESULTS:Oligosaccharides: S-, U- and CSF-oligosaccharides decreased 88.6% (CI -92.0 -85.2, p < 0.001), 54.1% (CI -69.5- -38.7, p < 0,001), and 25.7% (CI -44.3- -7.1, p < 0.05), respectively. Biomarkers: CSF-Tau- and GFA-protein decreased 15%, p < 0.009) and 32.5, p < 0.001 respectively. Motor function: Improvements in 3MSCT (31 steps (CI 6.8-40.5, p < 0.01) and in 6MWT (60.4 m (CI -8.9 -51.1, NS) were achieved. Cognitive function: Improvement in the total Equivalence Age of 4 months (0.34) was achieved in the Leiter R test (CI -0.2-0.8, NS). CONCLUSIONS: These data suggest that rhLAMAN may be an encouraging new treatment for patients with alpha-mannosidosis.The study is designed to continue for a total of 18 months. Longer-term follow-up of patients in this study and the future placebo-controlled phase 3 trial are needed to provide greater support for the findings in this study.
Authors: C M Eng; N Guffon; W R Wilcox; D P Germain; P Lee; S Waldek; L Caplan; G E Linthorst; R J Desnick Journal: N Engl J Med Date: 2001-07-05 Impact factor: 91.245
Authors: C M Eng; M Banikazemi; R E Gordon; M Goldman; R Phelps; L Kim; A Gass; J Winston; S Dikman; J T Fallon; S Brodie; C B Stacy; D Mehta; R Parsons; K Norton; M O'Callaghan; R J Desnick Journal: Am J Hum Genet Date: 2001-02-01 Impact factor: 11.025
Authors: David Hessl; Danh V Nguyen; Cherie Green; Alyssa Chavez; Flora Tassone; Randi J Hagerman; Damla Senturk; Andrea Schneider; Amy Lightbody; Allan L Reiss; Scott Hall Journal: J Neurodev Disord Date: 2009-03 Impact factor: 4.025
Authors: Line Borgwardt; Nathalie Guffon; Yasmina Amraoui; Christine I Dali; Linda De Meirleir; Mercedes Gil-Campos; Bénédicte Heron; Silvia Geraci; Diego Ardigò; Federica Cattaneo; Jens Fogh; J M Hannerieke Van den Hout; Michael Beck; Simon A Jones; Anna Tylki-Szymanska; Ulla Haugsted; Allan M Lund Journal: J Inherit Metab Dis Date: 2018-05-30 Impact factor: 4.982
Authors: Abirami Kugadas; Jennifer Geddes-McAlister; Emilia Guy; Antonio DiGiandomenico; David B Sykes; Michael K Mansour; Rossen Mirchev; Mihaela Gadjeva Journal: J Leukoc Biol Date: 2019-01-28 Impact factor: 4.962
Authors: Allan M Lund; Line Borgwardt; Federica Cattaneo; Diego Ardigò; Silvia Geraci; Mercedes Gil-Campos; Linda De Meirleir; Cécile Laroche; Philippe Dolhem; Duncan Cole; Anna Tylki-Szymanska; Monica Lopez-Rodriguez; Encarna Guillén-Navarro; Christine I Dali; Bénédicte Héron; Jens Fogh; Nicole Muschol; Dawn Phillips; J M Hannerieke Van den Hout; Simon A Jones; Yasmina Amraoui; Paul Harmatz; Nathalie Guffon Journal: J Inherit Metab Dis Date: 2018-05-03 Impact factor: 4.982